Top Markets
#1 Black Phoenix Black Phoenix +21,376.82%
#2 Nesa Nesa +739.84%
#3 ADO Protocol ADO Protocol +101.31%
#4 Cortex Cortex +93.15%
#5 Ontology Gas Ontology Gas +78.86%
#6 Kinesis Silver Kinesis Silver +52.87%
#7 OpenEden OpenEden +40.75%
#8 Magma Finance Magma Finance +33.31%
#9 QuantixAI QuantixAI +23.21%
#10 EXOD EXOD +22.78%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Orient Pharma Co., Ltd. Orient Pharma Co., Ltd.

Orient Pharma Co., Ltd.

4166
Rank in Stocks #18706
Orient Pharma Co., Ltd., established in Taipei, Taiwan, in 2008, is a global... Orient Pharma Co., Ltd., established in Taipei, Taiwan, in 2008, is a global pharmaceutical company engaged in the research, development, production, and sales of medicinal products. Its extensive pipeline addresses diverse therapeutic areas, including psychiatric disorders such as anti-psychotics and psychostimulants, neurological conditions like Parkinson's and Alzheimer's diseases, and treatments for sialorrhea, tuberculosis, and attention deficit hyperactivity disorder (ADHD). Beyond its drug portfolio, the company is also at the forefront of developing advanced drug delivery technologies, featuring multi-stage controlled release systems, transdermal patches, orally disintegrating tablets, sustained-release formulations, and microgranule technology.
Share Price
$0.77907619
Market Cap
$189.34M
Change (1 day)
0.41%
Change (1 year)
-7.35%
Country
TW
Trade Orient Pharma Co., Ltd. (4166)

Category

Healthcare
Revenue for Orient Pharma Co., Ltd. (4166)
Revenue in Aug 2026 TTM: 0
According to Orient Pharma Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Orient Pharma Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 $4.55B -
HK